Iridex Stock Price, News & Analysis

Iridex (Nasdaq: IRIX) announced a newly published computational study in Translational Vision Science & Technology modeling thermal dynamics of transscleral glaucoma lasers.

The Monte Carlo simulations compared continuous-wave TSCPC (CW-TSCPC) and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3. Results: CW-TSCPC produced a ~2 mm thermal zone with temperatures >100°C for ~2.2 seconds, while MicroPulse TLT produced a smaller 0.6–1.2 mm zone with peak temperatures below 100°C and more uniform heat distribution.

Authors say both techniques lie on a thermal continuum and may serve complementary clinical roles with further optimization.

Iridex (NASDAQ: IRIX) will participate in the Sidoti Year-End Virtual Investor Conference with management presenting on Thursday, December 11, 2025 at 10:45 AM ET. Interested parties can access a live and archived webcast via the company’s Investor Relations Event Calendar at www.IRIDEX.com. The presentation provides investors a direct opportunity to hear company updates and ask questions during the scheduled webcast.

Iridex (NASDAQ: IRIX) reported third quarter 2025 results with revenue of $12.5M, up 8% year‑over‑year, driven by higher Cyclo G6 probe and Pascal retina system sales.

Key metrics: Cyclo G6 revenue $3.5M (+13%), retina revenue $6.7M (+4%), gross profit $4.0M (32.1% margin), operating expenses $5.4M (down 12%), adjusted EBITDA loss $0.131M (improved $1.3M), and cash $5.6M (down $1.2M).

The company expects adjusted EBITDA positive for full‑year 2025 and to achieve cash flow breakeven in Q4 2025.

Iridex (Nasdaq: IRIX) will release third quarter 2025 financial results and provide a business update after market close on Tuesday, November 11, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET the same day.

Investors can join by dialing +1-888-596-4144 (US) or +1-646-968-2525 (international) and using Conference ID: 1504499. A live and recorded webcast will be posted on the company’s Investors > Event Calendar page at www.iridex.com.

Iridex Corporation (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has successfully regained compliance with Nasdaq's continued listing requirements. The company had received a non-compliance notice on May 14, 2025, due to falling below the minimum stockholders' equity requirement of $2.5 million based on their Q1 2025 10-Q filing.

On August 27, 2025, Nasdaq formally confirmed that Iridex had regained compliance with Rule 5550(b)(1) following the company's Q2 2025 10-Q filing on August 12, 2025, which demonstrated sufficient stockholders' equity. The compliance matter has been resolved and closed.

Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, reported its Q2 2025 financial results. The company achieved total revenue of $13.6 million, representing 7% year-over-year growth and 14% sequential growth.

Key highlights include Cyclo G6 product family revenue of $3.3 million (flat year-over-year), with 13,100 probes and 35 laser systems sold. Retina product revenue grew 10% year-over-year to $8.0 million. The company reduced operating expenses by 28% and achieved its third consecutive quarter of positive non-GAAP adjusted EBITDA. However, gross margin declined to 34.5% from 40.7% in Q2 2024.

The company reported a net loss of $1.0 million ($0.06 per share) and maintains $6.8 million in cash. For 2025, Iridex aims to achieve cash flow breakeven and positive adjusted EBITDA with revenue consistent with 2024 levels.

Iridex (Nasdaq: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases, has scheduled its second quarter 2025 financial results release for August 12, 2025 after market close.

The company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET on the same day. Investors can join via phone at +1-888-596-4144 using passcode 2197032, or access the webcast through Iridex's investor relations website.

Iridex Corporation (NASDAQ: IRIX) announced the enrollment of the first patient in the independent DAME Trial, evaluating the combination of MicroPulse technology with anti-VEGF therapy for severe diabetic macular edema (DME). The UK-based study, led by Professor Noemi Lois at Queen's University Belfast, aims to enroll 264 participants across 20 clinical sites.

The trial will assess the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-VEGF therapy. The study focuses on patients with severe DME, defined by central retinal subfield thickness ≥400 μm. The research is funded by the National Institute for Health Research (NIHR) and utilizes Iridex's IQ 577® laser system with MicroPulse® treatment mode and TxCell® Scanning Delivery Device.

Iridex Corporation (IRIX) reported its Q1 2025 financial results, showing modest growth and operational improvements. Total revenue reached $11.9 million, up slightly from $11.8 million in Q1 2024. The Cyclo G6 product family revenue increased 8% year-over-year to $3.2 million, with 13,900 probes and 24 Glaucoma Laser Systems sold. Retina product revenue declined 3% to $6.6 million. Notable improvements include a 32% reduction in operating expenses and positive adjusted EBITDA of $0.4 million, compared to a $2.5 million loss last year. The company strengthened its balance sheet through a $10 million strategic investment from Novel Inspiration. Gross margin improved to 42.5% from 37.9% in Q1 2024. Net loss decreased to $1.7 million ($0.10 per share) from $3.5 million ($0.21 per share) year-over-year. The company aims to achieve cash flow breakeven and maintain positive adjusted EBITDA in 2025.